SCHEMBL4676243

SCHEMBL4676243

O=C(O)C(O)=CC(=O)c1ccn(Cc2ccncc2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.40
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TSHR P16473 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CACNA1G O43497 4/20 0.36
CACNA1I Q9P0X4 4/20 0.36
KDM4E B2RXH2 4/20 0.36
ALDH1A1 P00352 3/20 0.35
MARS1 P56192 1/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
NPC1 O15118 3/20 0.34
RAB9A P51151 3/20 0.34
CACNA1H O95180 3/20 0.33
KDM4C Q9H3R0 1/20 0.33
PTGER1 P34995 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4671228 0.89 HDAC1 (0.50) HDAC1LMNASMN1; SMN2CACNA1GCACNA1I
SCHEMBL4678097 0.85 NPC1 (0.45) HDAC1LMNASMN1; SMN2TSHRHTT
SCHEMBL4673761 0.85 HDAC1 (0.39) HDAC1LMNASMN1; SMN2CACNA1GCACNA1I
SCHEMBL4672568 0.85 CACNA1G (0.47) HDAC1LMNASMN1; SMN2TSHRCACNA1G
SCHEMBL4671336 0.83 ALDH1A1 (0.43) HDAC1LMNASMN1; SMN2HTTCACNA1G
SCHEMBL4676077 0.82 CACNA1G (0.50) HDAC1CACNA1GCACNA1IALDH1A1MEN1
SCHEMBL4675432 0.79 L3MBTL1 (0.52) HDAC1SMN1; SMN2KDM4EALDH1A1KMT2A
SCHEMBL4675177 0.78 ALDH1A1 (0.41) HDAC1LMNASMN1; SMN2TSHRNPSR1
SCHEMBL4672484 0.78 HDAC1 (0.36) HDAC1LMNASMN1; SMN2TSHRHTT
SCHEMBL4674961 0.78 LMNA (0.34) HDAC1LMNASMN1; SMN2TSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 HDAC1 250/4885LMNA 659/4885SMN1; SMN2 4107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.